By Fineline Cube Gilead Sciences, Inc. (NASDAQ: GILD) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for its investigational bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN), a once-daily, single-tablet regimen for the treatment of virologically suppressed adults with HIV. The FDA has set a target action date of August 27, 2026, for its regulatory decision.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | U.S. Food and Drug Administration (FDA) |
| Application Type | New Drug Application (NDA) |
| Product | Bictegravir 75 mg/Lenacapavir 50 mg (BIC/LEN) – single-tablet regimen |
| Indication | Treatment of virologically suppressed adults with HIV |
| Dosing | Once-daily oral administration |
| PDUFA Date | August 27, 2026 |
| Review Status | Standard review (implied by 10-month PDUFA timeline) |
Drug Profile & Mechanism of Action
- Bictegravir Component: Globally guideline-recommended integrase strand transfer inhibitor (INSTI) targeting the viral integrase enzyme with a high barrier to resistance
- Lenacapavir Component: First-in-class capsid inhibitor with a novel mechanism of action showing no cross-resistance to other antiretroviral drug classes
- Combination Rationale: Dual-mechanism approach leveraging complementary antiviral activities to maintain viral suppression while potentially improving tolerability and convenience
- Usage Context: Bictegravir is indicated for HIV treatment only in combination with other antiretroviral agents, consistent with current standard of care
Clinical & Competitive Context
| Aspect | Detail |
|---|---|
| Target Population | Virologically suppressed adults with HIV currently on stable antiretroviral therapy |
| Therapeutic Goal | Maintenance therapy enabling simplified, once-daily single-tablet regimen |
| Current Standard | Multiple two-drug and three-drug regimens available, including Gilead’s own Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) |
| Differentiation | Incorporation of lenacapavir’s novel capsid inhibition mechanism may offer advantages in patients with resistance concerns or tolerability issues |
| Market Position | Would represent Gilead’s next-generation HIV maintenance option, building on established INSTI franchise |
Strategic Implications & Market Outlook
- Franchise Extension: BIC/LEN would complement Gilead’s existing HIV portfolio, which generated approximately $16 billion in 2025 revenue
- Competitive Landscape: Enters increasingly competitive two-drug maintenance market against options like dolutegravir/lamivudine (Dovato) and rilpivirine/cabotegravir long-acting injectable
- Commercial Potential: Successful approval could capture significant market share from existing three-drug regimens seeking simplification without compromising efficacy
- Pipeline Synergy: Leverages Gilead’s established expertise in INSTIs while introducing novel capsid inhibition technology through lenacapavir
- Global Strategy: U.S. approval would likely support regulatory filings in other major markets, particularly given bictegravir’s established global presence
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for BIC/LEN. Actual results may differ due to risks including FDA review outcomes, competitive dynamics, and market adoption patterns.-Fineline Info & Tech